Investigational drugs for vasospasm after subarachnoid hemorrhage

References

• Findlay JM, Nisar J, Darsaut T. Cerebral vasospasm: a review. Can J Neurol Sci. 2016;43(1):15–32.
   PubMed Web of Science ®Google Scholar
• de Oliveira Manoel AL, Goffi A, Marotta TR, et al. The critical care management of poor-grade subarachnoid haemorrhage. Crit Care. 2016;20:21.
   PubMed Web of Science ®Google Scholar
• Kramer AH, Zygun DA. Do neurocritical care units save lives? Measuring the impact of specialized ICUs. Neurocrit Care. 2011;14(3):329–333.
   PubMed Web of Science ®Google Scholar
• Grasso G, Alafaci C, Macdonald RL. Management of aneurysmal subarachnoid hemorrhage: state of the art and future perspectives. Surg Neurol Int. 2017;8:11.
   PubMedGoogle Scholar
• Suarez JI. Diagnosis and management of subarachnoid hemorrhage. Continuum (MinneapMinn). Neurocritical Care. 2015;21(5):1263–1287.
   Google Scholar
• Eisenhut M. Vasospasm in cerebral inflammation. Int J Inflam. 2014;2014:509707.
   PubMedGoogle Scholar
• Kiser TH. Cerebral vasospasm in critically III patients with aneurysmal subarachnoid hemorrhage: does the evidence support the ever-growing list of potential pharmacotherapy interventions? Hosp Pharm. 2014;49(10):923–941.
   PubMedGoogle Scholar
• Rabinstein AA, Weigand S, Atkinson JL, et al. Patterns of cerebral infarction in aneurysmal subarachnoid hemorrhage. Stroke. 2005;36(5):992–997.
   PubMed Web of Science ®Google Scholar
• Naraoka M, Matsuda N, Shimamura N, et al. The role of arterioles and the microcirculation in the development of vasospasm after aneurysmal SAH. Biomed Res Int. 2014;2014:253746.
   PubMedGoogle Scholar
• Wartenberg KE, Schmidt JM, Mayer SA. Multimodality monitoring in neurocritical care. Crit Care Clin. 2007;23(3):507–538.
   PubMed Web of Science ®Google Scholar
• Citerio G, Oddo M, Taccone FS. Recommendations for the use of multimodal monitoring in the neurointensive care unit. CurrOpinCrit Care. 2015;21(2):113–119.
   PubMed Web of Science ®Google Scholar
• Grosset DG, Georgiadis D, Cowburn P, et al. Transcranial Doppler for emboli. Neurology. 1994;44(10):1980–1981.
   PubMed Web of Science ®Google Scholar
• Rabinstein AA, Friedman JA, Nichols DA, et al. Predictors of outcome after endovascular treatment of cerebral vasospasm. AJNR Am J Neuroradiol. 2004;25(10):1778–1782.
   PubMed Web of Science ®Google Scholar
• Ohkuma H, Manabe H, Tanaka M, et al. Impact of cerebral microcirculatory changes on cerebral blood flow during cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2000;31(7):1621–1627.
   PubMed Web of Science ®Google Scholar
• Brady KM, Lee JK, Kibler KK, et al. Continuous measurement of autoregulation by spontaneous fluctuations in cerebral perfusion pressure: comparison of 3 methods. Stroke. 2008;39(9):2531–2537.
   PubMed Web of Science ®Google Scholar
• Budohoski KP, Czosnyka M, Smielewski P, et al. Impairment of cerebral autoregulation predicts delayed cerebral ischemia after subarachnoid hemorrhage: a prospective observational study. Stroke. 2012;43(12):3230–3237.
   PubMed Web of Science ®Google Scholar
• Calviere L, Nasr N, Arnaud C, et al. Prediction of delayed cerebral ischemia after subarachnoid hemorrhage using cerebral blood flow velocities and cerebral autoregulation assessment. Neurocrit Care. 2015;23(2):253–258.
   PubMed Web of Science ®Google Scholar
• Dennis LJ, Claassen J, Hirsch LJ, et al. Nonconvulsive status epilepticus after subarachnoid hemorrhage. Neurosurgery. 2002;51(5):1136–1143; discussion 1144.
   PubMed Web of Science ®Google Scholar
• Claassen J, Hirsch LJ, Frontera JA, et al. Prognostic significance of continuous EEG monitoring in patients with poor-grade subarachnoid hemorrhage. Neurocrit Care. 2006;4(2):103–112.
   PubMed Web of Science ®Google Scholar
• Herman ST, Abend NS, Bleck TP, et al. Consensus statement on continuous EEG in critically ill adults and children, part I: indications. J Clin Neurophysiol. 2015;32(2):87–95.
   PubMed Web of Science ®Google Scholar
• Kondziella D, Friberg CK, Wellwood I, et al. Continuous EEG monitoring in aneurysmal subarachnoid hemorrhage: a systematic review. Neurocrit Care. 2015;22(3):450–461.
   PubMed Web of Science ®Google Scholar
• O’Gorman RL, Poil SS, Brandeis D, et al. Coupling between resting cerebral perfusion and EEG. Brain Topogr. 2013;26(3):442–457.
   PubMed Web of Science ®Google Scholar
• Claassen J, Hirsch LJ, Kreiter KT, et al. Quantitative continuous EEG for detecting delayed cerebral ischemia in patients with poor-grade subarachnoid hemorrhage. Clin Neurophysiol. 2004;115(12):2699–2710.
   PubMed Web of Science ®Google Scholar
• Gollwitzer S, Groemer T, Rampp S, et al. Early prediction of delayed cerebral ischemia in subarachnoid hemorrhage based on quantitative EEG: a prospective study in adults. Clin Neurophysiol. 2015;126(8):1514–1523.
   PubMed Web of Science ®Google Scholar
• Burrell C, Avalon NE, Siegel J, et al. Precision medicine of aneurysmal subarachnoid hemorrhage, vasospasm and delayed cerebral ischemia. Expert Rev Neurother. 2016;16(11):1251–1262.
   PubMed Web of Science ®Google Scholar
• Haws CW, Gourley JK, Heistad DD. Effects of nimodipine on cerebral blood flow. J PharmacolExpTher. 1983;225(1):24–28.
   PubMed Web of Science ®Google Scholar
• Towart R, Kazda S. The cellular mechanism of action of nimodipine (BAY e 9736), a new calcium antagonist [proceedings]. Br J Pharmacol. 1979;67(3):409P–410P.
   PubMed Web of Science ®Google Scholar
• Müller-Schweinitzer E, Neumann P. In vitro effects of calcium antagonists PN 200-110, nifedipine, and nimodipine on human and canine cerebral arteries. J Cereb Blood Flow Metab. 1983;3(3):354–361.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Gotoh F, Muramatsu F, et al. Effect of nimodipine, a calcium antagonist, on cerebral vasospasm after subarachnoid hemorrhage in cats. Arzneimittelforschung. 1982;32(12):1529–1534.
   PubMed Web of Science ®Google Scholar
• Auer LM, Ito Z, Suzuki A, et al. Prevention of symptomatic vasospasm by topically applied nimodipine. ActaNeurochir (Wien). 1982;63(1–4):297–302.
   PubMed Web of Science ®Google Scholar
• Allen GS, Ahn HS, Preziosi TJ, et al. Cerebral arterial spasm–a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983;308(11):619–624.
   PubMed Web of Science ®Google Scholar
• Pickard JD, Murray GD, Illingworth R, et al. Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial. BMJ. 1989;298(6674):636–642.
   PubMedGoogle Scholar
• Choi HA, Ko SB, Chen H, et al. Acute effects of nimodipine on cerebral vasculature and brain metabolism in high grade subarachnoid hemorrhage patients. Neurocrit Care. 2012;16(3):363–367.
   PubMed Web of Science ®Google Scholar
• Sandow N, Diesing D, Sarrafzadeh A, et al. Nimodipine dose reductions in the treatment of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2016;25(1):29–39.
   PubMed Web of Science ®Google Scholar
• Soppi V, Kokki H, Koivisto T, et al. Early-phase pharmacokinetics of enteral and parenteral nimodipine in patients with acute subarachnoid haemorrhage - a pilot study. Eur J Clin Pharmacol. 2007;63(4):355–361.
   PubMed Web of Science ®Google Scholar
• Scheller C, Wienke A, Wurm F, et al. Enteral or parenteral nimodipine treatment: a comparative pharmacokinetic study. J Neurol Surg A Cent EurNeurosurg. 2014;75(2):84–90.
   PubMedGoogle Scholar
• Abboud T, Regelsberger J. Serum levels of nimodipine in enteral and parenteral administration in patients with aneurysmal subarachnoid hemorrhage. ActaNeurochir (Wien). 2015;157(7):1133–1134.
   PubMed Web of Science ®Google Scholar
• Vinge E, Andersson KE, Brandt L, et al. Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage. Eur J Clin Pharmacol. 1986;30(4):421–425.
   PubMed Web of Science ®Google Scholar
• Liu XQ, Ren YL, Qian ZY, et al. Enzyme kinetics and inhibition of nimodipine metabolism in human liver microsomes. ActaPharmacol Sin. 2000;21(8):690–694.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhai D, He H, et al. Effects of CYP3A5, MDR1 and CACNA1C polymorphisms on the oral disposition and response of nimodipine in a Chinese cohort. Eur J Clin Pharmacol. 2009;65(6):579–584.
   PubMed Web of Science ®Google Scholar
• Guengerich FP, Brian WR, Iwasaki M, et al. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem. 1991;34(6):1838–1844.
   PubMed Web of Science ®Google Scholar
• Mück W, Ahr G, Kuhlmann J. Nimodipine. Potential for drug-drug interactions in the elderly. Drugs Aging. 1995;6(3):229–242.
   PubMed Web of Science ®Google Scholar
• Naidech AM, Kreiter KT, Janjua N, et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke. 2005;36(3):583–587.
   PubMed Web of Science ®Google Scholar
• Soppi V, Karamanakos PN, Koivisto T, et al. A randomized outcome study of enteral versus intravenous nimodipine in 171 patients after acute aneurysmal subarachnoid hemorrhage. World Neurosurg. 2012;78(1–2):101–109.
   PubMed Web of Science ®Google Scholar
• Kronvall E, Undrèn P, Romner B, et al. Nimodipine in aneurysmal subarachnoid hemorrhage: a randomized study of intravenous or peroral administration. J Neurosurg. 2009;110(1):58–63.
   PubMed Web of Science ®Google Scholar
• Albanna W, Weiss M, Conzen C, et al. Systemic and cerebral concentration of nimodipine during established and experimental vasospasm treatment. World Neurosurg. 2017;102:459–465.
   PubMed Web of Science ®Google Scholar
• Hockel K, Diedler J, Steiner J, et al. Effect of intra-arterial and intravenous nimodipine therapy of cerebral vasospasm after SAH on cerebrovascular reactivity and oxygenation. World Neurosurg. 2017;101:372–378.
   PubMed Web of Science ®Google Scholar
• Cho S, Bales J, Tran TK, et al. Effects of 14 versus 21 days of nimodipine therapy on neurological outcomes in aneurysmal subarachnoid hemorrhage patients. Ann Pharmacother. 2016;50(9):718–724.
   PubMed Web of Science ®Google Scholar
• Koskimäki J, Tarkia M, Ahtola-Sätilä T, et al. Intracranial biodegradable silica-based nimodipine drug release implant for treating vasospasm in subarachnoid hemorrhage in an experimental healthy pig and dog model. Biomed Res Int. 2015;2015:715752.
   PubMedGoogle Scholar
• Hänggi D, Etminan N, Macdonald RL, et al. NEWTON: nimodipine microparticles to enhance recovery while reducing toxicity after subarachnoid hemorrhage. Neurocrit Care. 2015;23(2):274–284.
   PubMed Web of Science ®Google Scholar
• Hänggi D, Etminan N, Aldrich F, et al. Randomized, open-label, phase 1/2a study to determine the maximum tolerated dose of intraventricular sustained release nimodipine for subarachnoid hemorrhage (NEWTON [nimodipine microparticles to enhance recovery while reducing toxicity after subarachnoid hemorrhage]). Stroke. 2017;48(1):145–151.
   PubMed Web of Science ®Google Scholar
• Lu N, Jackson D, Luke S, et al. Intraventricular nicardipine for aneurysmal subarachnoid hemorrhage related vasospasm: assessment of 90 days outcome. Neurocrit Care. 2012;16(3):368–375.
   PubMed Web of Science ®Google Scholar
• Ko SB, Choi HA, Helbok R, et al. Acute effects of intraventricular nicardipine on cerebral hemodynamics: a preliminary finding. Clin NeurolNeurosurg. 2016;144:48–52.
   PubMed Web of Science ®Google Scholar
• Arakawa Y, Kikuta K, Hojo M, et al. Milrinone for the treatment of cerebral vasospasm after subarachnoid hemorrhage: report of seven cases. Neurosurgery. 2001;48(4): 723–728. discussion 728–730.
   PubMed Web of Science ®Google Scholar
• Stuart D, Christian R, Uschmann H. Effectiveness of intrathecal nicardipine on cerebral vasospasm in non-traumatic subarachnoid hemorrhage: a systematic review protocol. JBI Database System Rev Implement Rep. 2017;15(3):628–637.
   PubMedGoogle Scholar
• Lannes M, Teitelbaum J, del Pilar Cortès M, et al. Milrinone and homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital protocol. Neurocrit Care. 2012;16(3):354–362.
   PubMed Web of Science ®Google Scholar
• Sadamasa N, Yoshida K, Narumi O, et al. Milrinone via lumbar subarachnoid catheter for vasospasm after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2014;21(3):470–475.
   PubMed Web of Science ®Google Scholar
• Taki W, Sakai N, Suzuki H, PRESAT Group. Determination of poor outcome after aneurysmal subarachnoid hemorrhage when both clipping and coiling are available: prospective registry of subarachnoid aneurysms treatment (PRESAT) in Japan. World Neurosurg. 2011;76:437–445.
   PubMed Web of Science ®Google Scholar
• Al. Tamimi YZ, Bhargava D, Feltbower RG, et al. Lumbar drainage of cerebrospinal fluid after aneurysmal subrachnoid hemorrhage: a prospective, randomized, controlled trial (LUMAS). Stroke. 2012;43:677–682.
   PubMed Web of Science ®Google Scholar
• Klimo P, Kestle JR, MacDonald JD, et al. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg. 2004;100(2):215–224.
   PubMed Web of Science ®Google Scholar
• Zeiler FA, Silvaggio J. Early angiographic resolution of cerebral vasospasm with high dose intravenous milrinone therapy. Case Rep Crit Care. 2015;2015:164597.
   PubMedGoogle Scholar
• Koyanagi M, Fukuda H, Lo B, et al. Effect of intrathecal milrinone injection via lumbar catheter on delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2017;3:1–6.
   Google Scholar
• Macdonald RL, Higashida RT, Keller E, et al. Preventing vasospasm improves outcome after aneurysmal subarachnoid hemorrhage: rationale and design of CONSCIOUS-2 and CONSCIOUS-3 trials. Neurocrit Care. 2010;13(3):416–424.
   PubMed Web of Science ®Google Scholar
• Rong WL, Xiao X, Zhao JL, et al. Different doses of clazosentan for aneurismal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. Am J Ther. 2016. DOI:10.1097/MJT.0000000000000432
   Google Scholar
• Dhar R, Misra H, Diringer MN. SANGUINATE™ (PEGylated carboxyhemoglobin bovine) improves cerebral blood flow to vulnerable brain regions at risk of delayed cerebral ischemia after subarachnoid hemorrhage. Neurocrit Care. 2017;27(3):341–349.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick PJ, Turner CL, Smith C, et al. Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial. Lancet Neurol. 2014;13(7):666–675.
   PubMed Web of Science ®Google Scholar
• Dorhout Mees SM, Algra A, Vandertop WP, et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet. 2012;380(9836):44–49.
   PubMed Web of Science ®Google Scholar
• Wong GK, Poon WS, Chan MT, et al. Intravenous magnesium sulphate for aneurysmal subarachnoid hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. Stroke. 2010;41(5):921–926.
   PubMed Web of Science ®Google Scholar
• Murata Y, Rosell A, Scannevin RH, et al. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke. 2008;39(12):3372–3377.
   PubMed Web of Science ®Google Scholar
• Steiner T, Juvela S, Unterberg A, et al. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013;35(2):93–112.
   PubMed Web of Science ®Google Scholar